Isatuximab

Current treatment landscape of newly diagnosed multiple myeloma 2:11
Current treatment landscape of newly diagnosed multiple myeloma
Faith Davies • 10 Dec 2021
An update on antibody-based treatment approaches in multiple myeloma 2:33
An update on antibody-based treatment approaches in multiple myeloma
Surbhi Sidana • 14 Dec 2021
Latest news in myeloma: MRD, BiTEs, and CAR T-cells 13:47
Latest news in myeloma: MRD, BiTEs, and CAR T-cells
Mohamad Mohty • 14 Dec 2021
Phase III trial of RVd induction with or without isatuximab in newly diagnosed myeloma 6:37
Phase III trial of RVd induction with or without isatuximab in newly diagnosed myeloma
Hartmut Goldschmidt • 10 Dec 2021
The role of immunotherapy in multiple myeloma 1:12
The role of immunotherapy in multiple myeloma
Nina Shah • 10 Dec 2021
Transplant: its role in 2021 and optimization 5:33
Transplant: its role in 2021 and optimization
Meral Beksac • 10 Sep 2021
Optimal treatment sequencing for relapsed/refractory myeloma 1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021
Replacing ASCT: CAR-T or bispecific antibodies? 2:52
Replacing ASCT: CAR-T or bispecific antibodies?
Parameswaran Hari • 2 Sep 2021
Early relapse: options for rescue 2:25
Early relapse: options for rescue
Maria-Victoria Mateos • 2 Sep 2021
Isatuximab short-duration fixed-volume infusion plus VRd for transplant-ineligible myeloma 3:52
Isatuximab short-duration fixed-volume infusion plus VRd for transplant-ineligible myeloma
Enrique Ocio • 6 Sep 2021
The DREAMM-5 PLATFORM trial 2:22
The DREAMM-5 PLATFORM trial
Paul Richardson • 10 Jul 2021
Update on the ICARIA-MM trial 7:58
Update on the ICARIA-MM trial
Paul Richardson • 10 Jul 2021
IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM 3:46
IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM
Roman Hajek • 10 Jun 2021
The antibody treatment landscape in myeloma 1:28
The antibody treatment landscape in myeloma
Sagar Lonial • 9 Jun 2021
CD38 and SLAMF7 targeting for multiple myeloma 2:49
CD38 and SLAMF7 targeting for multiple myeloma
Enrique Ocio • 26 May 2021
Updates on belantamab mafodotin for myeloma 2:38
Updates on belantamab mafodotin for myeloma
Claudio Cerchione • 25 May 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals